AMRN Stock Recent News
AMRN LATEST HEADLINES
Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.
Amarin recently acquired a completely revamped management. There seems to be no radical shift in strategy, however. Therefore, there is no radical change in my negative opinion on the outlook.
Start Time: 17:40 January 1, 0000 6:14 PM ET Amarin Corporation plc (NASDAQ:AMRN ) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023, 17:40 PM ET Company Participants Aaron Berg - Interim President and CEO Tom Reilly - CFO Conference Call Participants Paul Choi - Goldman Sachs Paul Choi Okay. We'll continue with our next session.
DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Aaron Berg, Amarin's Interim President and Chief Executive Officer and Tom Reilly, Amarin's Chief Financial Officer, will present at two upcoming investor conferences:
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin's senior management team to discuss the Company's first quarter 2023 financial results on Wednesday, May 3rd, 2023 at 8:00 a.m. ET.
Sarissa Capital has taken full control of Amarin. The previous management was doing some slow but decent work, but did not get time to show results.
Two economic reports point to a possible recession later this year. Investors sold off risky biotech stocks as a result.
Shares of Amarin Corp. AMRN, -5.19% rose dropped 5.5% toward a near three-month low in premarket trading Friday, after the biopharmaceutical company focused on therapies for cardiovascular health disclosed that Chief Executive Karim Mikhail has resigned, effective immediately, after about 19 months in the role. “Mr. Mikhail has asserted that he is entitled to severance payments as the result of his resignation, which the company disagrees with and intends to dispute,” Amarin said in a statement.